TRPA1 is a promising therapeutic solution for MS patients, considering that knockout studies led to the discovery of a potential pathophysiological role of the channel in astrogliosis and oligodendrocyte apoptosis [24]. The gene discussed is TRPA1; the disease is myeloid sarcoma.